Profile data is unavailable for this security.
About the company
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
- Revenue in HKD (TTM)12.92bn
- Net income in HKD1.28bn
- Incorporated2011
- Employees6.19k
- LocationInnovent Biologics Inc168Dongping Street, Suzhou Industrial ParkSUZHOU 215123ChinaCHN
- Websitehttps://www.innoventbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | 2.77bn | -6.23bn | 114.56bn | 725.00 | -- | -- | -- | 41.43 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Ipsen SA | 36.46bn | 4.11bn | 114.78bn | 5.36k | 27.74 | 2.82 | 10.23 | 3.15 | 5.32 | 5.32 | 47.09 | 52.42 | 0.5875 | 2.85 | 5.30 | -- | 6.66 | 9.15 | 8.54 | 12.07 | 80.89 | 82.61 | 11.33 | 15.86 | 1.79 | 122.28 | 0.1845 | -- | 9.92 | 7.90 | 24.61 | -4.01 | 18.50 | -- |
| CSPC Pharmaceutical Group Ltd | 29.65bn | 4.59bn | 116.84bn | 19.27k | 25.28 | -- | 55.18 | 3.94 | 0.4011 | 0.4011 | 2.59 | -- | -- | -- | -- | 1,385,372.00 | -- | 14.64 | -- | 19.49 | 66.23 | 72.50 | 15.54 | 19.11 | -- | -- | -- | 41.10 | -7.76 | 5.59 | -26.31 | 3.11 | 4.76 | 21.28 |
| Torrent Pharmaceuticals Ltd | 10.57bn | 1.85bn | 119.09bn | 16.11k | 64.48 | 16.33 | 46.85 | 11.27 | 63.23 | 63.23 | 361.86 | 249.64 | 0.8005 | 1.26 | 6.17 | 7,604,203.00 | 13.99 | 9.54 | 20.08 | 14.72 | 75.69 | 72.56 | 17.47 | 14.14 | 0.8352 | 14.67 | 0.2504 | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
| Moderna Inc | 17.45bn | -24.35bn | 122.48bn | 5.80k | -- | 1.68 | -- | 7.02 | -8.05 | -8.05 | 5.76 | 23.86 | 0.1598 | 2.19 | 1.71 | 384,827.60 | -22.31 | 13.72 | -25.91 | 18.76 | 63.49 | 76.34 | -139.61 | 23.74 | 3.73 | -- | 0.0061 | 0.00 | -52.75 | 121.86 | 24.46 | -- | 101.61 | -- |
| Sino Biopharmaceutical Ltd | 34.57bn | 4.41bn | 123.45bn | 23.06k | 26.94 | 3.12 | 13.43 | 3.57 | 0.2443 | 0.2426 | 1.91 | 2.11 | 0.4317 | 2.83 | 3.98 | 1,417,993.00 | 9.56 | 12.16 | 18.52 | 20.91 | 81.77 | 80.75 | 22.15 | 26.50 | 1.28 | -- | 0.2071 | 27.19 | 10.18 | 3.56 | 3.93 | -7.01 | -7.91 | 6.66 |
| Swedish Orphan Biovitrum AB (publ) | 24.72bn | 418.39m | 128.45bn | 1.89k | 316.62 | 3.76 | 37.06 | 5.20 | 1.30 | 1.30 | 81.42 | 109.12 | 0.3953 | 1.28 | 5.11 | 14,956,040.00 | 0.6663 | 3.92 | 0.8337 | 5.04 | 78.89 | 77.84 | 1.69 | 10.91 | 0.585 | 9.77 | 0.2336 | 0.00 | 8.50 | 13.10 | -87.70 | -31.82 | -3.93 | -- |
| Sichuan Biokin Pharmaceutical Co Ltd | 2.52bn | -965.39m | 135.33bn | 2.52k | -- | 16.66 | -- | 53.68 | -2.14 | -2.14 | 5.54 | 17.37 | 0.2309 | 1.44 | 2.31 | 883,003.90 | -8.84 | 27.12 | -11.31 | 47.59 | 89.15 | 86.86 | -38.29 | 29.03 | 5.23 | -- | 0.3446 | 0.00 | 936.31 | 37.00 | 575.02 | 243.69 | 31.86 | -- |
| Divi's Laboratories Ltd | 8.90bn | 2.14bn | 141.70bn | 18.30k | 66.19 | -- | 56.06 | 15.92 | 93.45 | 93.45 | 388.82 | -- | -- | -- | -- | 5,636,066.00 | -- | 15.81 | -- | 17.33 | 61.65 | 55.90 | 24.04 | 25.82 | -- | -- | -- | 35.19 | 19.31 | 11.65 | 36.94 | 9.74 | 3.98 | 13.40 |
| Viatris Inc | 110.40bn | -28.85bn | 142.15bn | 32.00k | -- | 1.20 | -- | 1.29 | -3.10 | -3.10 | 11.96 | 13.13 | 0.3417 | 2.09 | 4.90 | 441,387.50 | -8.93 | -0.1756 | -10.89 | -0.2096 | 39.36 | 40.66 | -26.13 | -0.5768 | 0.793 | 2.79 | 0.4868 | -- | -4.46 | 5.09 | -1,259.42 | -- | -3.10 | -- |
| Roivant Sciences Ltd | 104.03m | -6.33bn | 149.64bn | 750.00 | -- | 4.45 | -- | 1,438.39 | -1.17 | -1.17 | 0.0193 | 6.02 | 0.0024 | -- | -- | 17,746.67 | -18.26 | 5.89 | -20.80 | 6.98 | 91.21 | 90.39 | -7,558.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| Innovent Biologics Inc | 12.92bn | 1.28bn | 154.52bn | 6.19k | 116.67 | 9.03 | 84.37 | 11.96 | 0.7633 | 0.7633 | 7.77 | 9.86 | 0.5205 | 1.80 | 7.39 | 2,282,825.00 | 5.16 | -8.71 | 6.52 | -10.73 | 85.69 | 84.74 | 9.91 | -24.84 | 2.39 | -- | 0.1898 | -- | 51.82 | 55.17 | 90.79 | -- | 35.02 | -- |
| Incyte Corp | 40.18bn | 10.06bn | 156.72bn | 2.84k | 15.73 | 3.87 | 14.53 | 3.90 | 6.40 | 6.40 | 25.61 | 26.04 | 0.8291 | 4.33 | 5.48 | 1,807,750.00 | 20.75 | 11.34 | 27.83 | 14.38 | 93.26 | 93.92 | 25.03 | 16.48 | 3.25 | -- | 0.0067 | 0.00 | 21.22 | 14.03 | 3,844.96 | -- | -20.67 | -- |
| United Therapeutics Corp | 24.45bn | 9.94bn | 160.23bn | 1.31k | 18.03 | 3.10 | 15.14 | 6.55 | 26.41 | 26.41 | 64.94 | 153.61 | 0.4323 | 2.21 | 9.78 | 2,397,242.00 | 17.57 | 13.61 | 19.48 | 14.84 | 88.59 | 90.79 | 40.65 | 37.81 | 6.07 | -- | 0.00 | 0.00 | 23.63 | 14.71 | 21.35 | -- | 24.11 | -- |
| Shionogi & Co Ltd | 23.81bn | 9.97bn | 160.92bn | 4.96k | 15.44 | 1.99 | 14.57 | 6.76 | 228.94 | 228.94 | 546.70 | 1,779.33 | 0.2869 | 0.8648 | 2.76 | 93,915,640.00 | 11.98 | 12.17 | 13.13 | 13.74 | 84.50 | 84.91 | 41.78 | 38.30 | 5.21 | -- | 0.0148 | 27.87 | 0.7325 | 5.62 | 5.19 | 6.88 | 34.66 | 12.30 |
Data as of Feb 13 2026. Currency figures normalised to Innovent Biologics Inc's reporting currency: Hong Kong Dollar HKD
21.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 02 May 2025 | 71.11m | 4.13% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 61.87m | 3.60% |
| BlackRock Fund Advisorsas of 09 Dec 2025 | 48.30m | 2.81% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 45.01m | 2.62% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 34.19m | 1.99% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 24.71m | 1.44% |
| BlackRock Advisors (UK) Ltd.as of 09 Dec 2025 | 23.13m | 1.34% |
| Capital International Ltd.as of 31 Dec 2025 | 22.02m | 1.28% |
| Capital Research & Management Co. (World Investors)as of 08 Jan 2026 | 21.77m | 1.27% |
| Hang Seng Investment Management Ltd.as of 09 Jan 2026 | 19.85m | 1.15% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
